Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC

25 Feb 2026
Guardant360® ctDNA liquid biopsy for treatment selection of patients with NSCLC
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Related MIMS Drugs

Resources

SG-GDH-001

SG-GDH-001

SG-GDH-001

SG-GDH-001